Thank you for participating in BIO-Europe® 2014
Download your messages and statistics, bookmark and set notifications to track your leads, all on partnering360®.
The majority of BIO-Europe® 2014 delegates are already members of partnering360®.
partnering360: maximize your productivity by engaging and finding partners 24/7. Synchronize your in-person partnering with your online activity — all in one place.
Save the date and check back in the coming weeks for information on next year's BIO-Europe, November 2–4, 2015 in Munich, Germany.
About the BIO-Europe® Conference
BIO-Europe® 2013 Highlights
- 3,202 attendees
- 17,874 one-to-one meetings
- 3,599 licensing opportunities posted
- 1,841 companies
- 184 company presentations
- 95 exhibitors
- 56 countries represented
- 18 workshops and panels
- 11 Academic Innovators™ presentations
Building value through partnerships
BIO-Europe® is Europe's largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. Produced with the support of BIO, it is regarded as a “must attend” event for the biotech industry.
Featuring EBD Group's sophisticated, web-based partnering system, partneringONE®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative start-ups. more ►
Join the conversation
Group members: 193
We take a look today at the partnering 360 blog: http://bit.ly/1wtvMa7
A compelling workshop called “The oncology watch list: Next gen immunotherapies” will take place January ...
Today at the partnering360 blog, we look at a company's best way to get their ...
One of the hottest topics at the past BIO-Europe event was immuno-oncology. Today, we ...
Who will you meet?
BIO-Europe plays host to executives from:
- Established and emerging biotech companies
- Pharmaceutical companies
- Academic innovators
- Private investors including venture capital and private equity
- Companies developing companion diagnostics
- Other industry related service companies